Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The result at week 68: Continued semaglutide 2.4 mg: lost an additional 7.9% of body weight (total loss from baseline: 17.4%) Switched to placebo: regained 6.9% of body weight (net loss from baseline: 5.0%) Thats a roughly 15-point difference in body weight between the two groups at the end of the trial, attributable entirely to whether the medication continued
Noom is marketing its GLP-1 microdoses as a more cost-effective way to lose weight with fewer side effects, which may affect GLP-1 drug adherence
48 These results suggest that prolonged CR may influence bone metabolism through mechanisms distinct from those observed in short-term interventions, highlighting the need for further investigation
Circulation 145(8):565574
US$ 25.78
US$ 24.82
US$ 24.95
